SCHEMBL4057352

SCHEMBL4057352

CCOC(=O)c1cnc2ccc3sccc3c2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.46
MEN1 O00255 6/20 0.46
MAPK10 P53779 1/20 0.45
MAPT P10636 4/20 0.43
KDM4E B2RXH2 4/20 0.42
GAA P10253 2/20 0.42
ATM Q13315 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 5/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
RECQL P46063 1/20 0.41
MAPK1 P28482 4/20 0.41
PKM P14618 2/20 0.40
LMNA P02545 2/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4047130 0.80 PDE4B (0.52) MAPTKDM4EGAAALDH1A1PKM
SCHEMBL6777873 0.79 CA12 (0.45) KMT2AMEN1MAPTKDM4EATM
SCHEMBL4050780 0.78 MAPT (0.61) KMT2AMEN1MAPTKDM4EGAA
SCHEMBL4904367 0.78 KMT2A (0.48) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL30629472 0.78 KMT2A (0.52) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL4906865 0.78 KMT2A (0.54) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL30629554 0.76 KMT2A (0.50) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL11691158 0.75 KMT2A (0.47) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL2911629 0.74 KMT2A (0.48) KMT2AMEN1MAPK10MAPTKDM4E
SCHEMBL2718914 0.73 KMT2A (0.50) KMT2AMEN1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2035434-A1 QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM Bayer Schering Pharma Aktiengesellschaft (DE) 2009-03-18 EP disclosed
US-20080056987-A1 Quinoline derivatives, their preparation, their use, and medicaments comprising them BAYER SCHERING PHARMA AG (DE) 2008-03-06 US disclosed
WO-2007147578-A1 QUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080056987-A1 Quinoline derivatives, their preparation, their use, and medicaments comprising them RECQL, NQO2, XDH KMT2A 1600/4885MEN1 634/4885MAPK10 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.